?> Oxford BioDynamics Plc to present at China BIO Conference - DirectorsTalk

Be sure to check our sister interview main ratings news website

Oxford BioDynamics Plc to present at China BIO Conference

Oxford BioDynamics Plc (LON:OBD), a biotechnology company focused on the discovery and development of epigenetic biomarkers based on regulatory genome architecture, for use within the pharmaceutical and biotechnology industry, today announced that it has been selected to present at the China BIO Partnering Forum in Shanghai on 8 May 2019 with a talk by the Company’s Chief Scientific Officer, Dr Alexandre Akoulitchev, entitled “EpiSwitch™ Biomarkers: Practical Applications For Predictive, Prognostic And Diagnostic Patient Stratifications”.

Alexandre Akoulitchev, Chief Scientific Officer, Oxford BioDynamics said:

“We are looking forward to establishing new partnerships for OBD’s EpiSwitch™ technology in China. Our experience includes working with American and European biopharmaceutical partners to enable precision medicine initiatives through the incorporation of our proprietary, epigenetic-based biomarker platform across the research and development value chain. Recent milestones include the co-development of a response biomarker to checkpoint inhibitor therapy in non-small cell lung cancer (NSCLC), a disease subtyping biomarker in diffuse B-cell lymphoma (DLBCL), a response biomarker to first line therapy in rheumatoid arthritis (RA), a disease progression biomarker in amyotrophic lateral sclerosis (ALS), and diagnostic and prognostic biomarkers for non-alcoholic steatohepatitis (NASH). Our partnering models are typically structured as milestone-driven, collaborative R&D and licensing deals and have already attracted significant interest from Chinese Biotech.”

The presentation will focus on validated EpiSwitch™ biomarker applications which have demonstrated high efficacy in predictive, prognostic and diagnostic patient stratifications for lung, haematological, prostate, thyroid and skin cancers. Baseline predictive stratifications by EpiSwitch™ for response to immune-checkpoint inhibitors are excellent surrogates for standard primary endpoints used in clinical trials, such as progression free survival. The company has recently entered into its fifth collaboration agreement for the development of predictive biomarkers for immuno-oncology therapeutics with leading pharmaceutical companies.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    X
    LinkedIn
    Oxford BioDynamics

    More articles like this

    Oxford BioDynamics

    How are EpiSwitch markers detected?

    8th July 2020

    Introduction: Getting the basics right Oxford BioDynamics’ (OBD) EpiSwitch™ biomarker discovery platform combined with their newly enhanced detection technology gives the company valuable quantitative insights into chromosome conformations (DNA protein complexes) that regulate normal and disease

    Oxford BioDynamics

    What is EpiSwitchTM and how is it used?

    3rd July 2020

    Oxford BioDynamics’ EpiSwitch™ technology is based on epigenetics, mechanisms that alter gene expression without altering the underlying DNA sequence and whose deregulation plays a role in the development of cancer, autoimmune, and neurologic diseases. Although DNA

    Oxford BioDynamics

    Sanders-Brown research highlights form of severe dementia

    1st July 2020

    The long-running study on aging and brain health at the University of Kentucky’s Sanders-Brown Center on Aging (SBCoA) Alzheimer’s Disease Center has once again resulted in important new findings – highlighting a complex and under-recognized form

    Oxford BioDynamics

    Researchers identify new genetic defect linked to ALS

    17th June 2020

    Mutations in the UBQLN2 gene, known to cause amyotrophic lateral sclerosis (ALS), promote the buildup of toxic waste in brain cells by preventing the normal function of two cellular degradation mechanisms, a study has found. In addition to its known role

    Oxford BioDynamics

    New questions about Covid-19

    3rd June 2020

    The coronavirus is known with certainty that it emerged in China in November and has since spread to almost the entire world, where it has infected more than 5 million people and killed at least 356,000. Older adults are more

    Oxford BioDynamics

    EpiSwitch technology selected as biomarker platform for COVID-19

    29th May 2020

    Oxford BioDynamics’ EpiSwitch technology has been chosen as the biomarker platform for prognostic and predictive profiling of COVID-19 patients in the GETAFIX clinical study.Institute of Infection, Immunity and Inflammation, University of Glasgow, and NHS Scotland are

    Oxford BioDynamics

    Rare Diseases Clinical Research Network Opens Online Survey on COVID-19

    21st May 2020

    The Rare Diseases Clinical Research Network (RDCRN) has opened an online survey to better understand how the COVID-19 outbreak is affecting people with rare diseases, their families, and caregivers. Survey questions cover a patient’s physical and mental health, supply of treatments, and

    Oxford BioDynamics

    Pandemic moves ALS Awareness Month events and activities online

    18th May 2020

    ALS Awareness Month has been observed each May since 1992. But this year, the COVID-19 pandemic has forced supporters to rethink ways to raise funds and awareness for amyotrophic lateral sclerosis (ALS). In previous years, May has been full of fundraising and educational activities

    Oxford BioDynamics

    ALS Awareness

    11th May 2020

    “I think it’s time we stop, children, what’s that sound? Everybody look what’s going down.” That call for awareness comes from the song “For What It’s Worth” by Buffalo Springfield. The song’s writer, Stephen Stills, penned the lyrics in

    Oxford BioDynamics

    ALS Awareness Month This May

    6th May 2020

    Within weeks following my ALS diagnosis, I faced my first ALS Awareness Month. At the time, I was still figuring out exactly what I had and how to pronounce amyotrophic lateral sclerosis. Never mind trying to educate others about it. I hated

    Oxford BioDynamics

    Microarray Facility

    29th April 2020

    The purpose-built Oxford Biodynamics Array facility offers a complete sample processing service for Comparative Genome Hybridization (CGH) using the Agilent microarray platform.  Agilent’s flexible SurePrint technology produces high-quality arrays of 60-mer oligonucleotides in a range of

    Oxford BioDynamics

    EpiSwitch biomarker discovery platform

    22nd April 2020

    INTRODUCTION • The EpiSwitch biomarker discovery platform detects systemic changes in the cellular genomic architecture using a microarray and PCR-based biomarker platform (Figure 1)1. It identifies and monitors chromosome conformation signatures (CCSs), key regulatory processes that

    © 2024 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.